<DOC>
	<DOCNO>NCT01505569</DOCNO>
	<brief_summary>This standard care treatment guideline high risk relapse solid tumor CNS tumor consist busulfan , melphalan , thiotepa conditioning ( solid tumor ) carboplatin thiotepa conditioning ( CNS tumor ) follow autologous peripheral blood stem cell transplant . For solid tumor , appropriate , disease specific radiation therapy day +60 . For CNS tumor , condition regimen autologous peripheral blood stem cell transplant give 3 cycle .</brief_summary>
	<brief_title>Auto Transplant High Risk Relapsed Solid CNS Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Retinoblastoma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Rhabdoid Tumor</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Hepatoblastoma</mesh_term>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>All patient must histological verification malignancy original diagnosis . Eligible Diseases Arm A : Solid Tumor Ewing 's Family Tumors ( ES/PNET/DSRCT ) metastatic time diagnosis and/or relapse therapy Renal Tumors relapse ( histology Wilm 's tumor ) diagnosis ( clear cell sarcoma Rhabdoid tumor ) Hepatoblastoma metastatic time diagnosis and/or relapse therapy Rhabdomyosarcoma metastatic time diagnosis and/or relapse therapy Soft Tissue Sarcoma chemotherapy responsive metastatic disease chemotherapy responsive relapse disease Primary Malignant Brain Neoplasms &lt; 18 year age diagnosis and/or relapse Retinoblastoma disseminate diagnosis and/or relapse Other High Risk Metastatic Relapsed Solid Tumors approve 2 pediatric hematology/oncology bone marrow transplant ( BMT ) physicians Arm B : Certain CNS tumor Medulloblastoma : Children le 36 month ( 3 year ) age time definitive surgery ( histopathologic diagnosis ) high risk Medulloblastoma , define one following : 1 . &gt; 1.5 cm2 residual disease follow resection Medulloblastoma histology 2. lumbar CSF cytology positive tumor cell analysis fluid collect either definitive surgery least 10 day definitive surgery 3 . MRI evidence ( ) gross nodular seed intracranial subarachnoid space ventricular system distant primary tumor site , M2 ; ( b ) gross nodular seed spinal subarachnoid space +/ evidence intracranial seeding , M3 ; ( c ) extraneural metastasis , M4 , Anaplastic Histologic Variant Medulloblastoma : less 70 year age , metastatic stage , total subtotal resection . Infant Medulloblastoma : Children le 8 month age time definitive surgery ( histopathologic diagnosis ) , histology , metastatic state , total subtotal resection . Supratentorial Primative NeuroEctodermal Tumor ( PNET ) : Children le 36 month ( 3 year ) age time definitive surgery ( histopathologic diagnosis ) without metastatic disease Atypical Teratoid/Rhabdoid Tumor ( AT/RT ) : le 70 year age CNS AT/RT ( without metastatic disease ) . Other High Risk CNS Tumors approve 2 physician ( least one oncologist one BMT physician ) . Arm C : Germ Cell Tumors Confirmation germ cell tumor ( GCT ) histology ( seminoma nonseminoma ) . Tumor may originate primary site . NOTE : In rare circumstance , patient allow enroll even pathologic diagnosis may establish . This would require clinical situation consistent diagnosis GCT ( testicular , peritoneal , retroperitoneal mediastinal mass , elevate tumor marker level { HCG ≥ 500 ; AFP ≥ 500 } typical pattern metastasis ) . 1 . One unfavorable prognostic feature achieve CR conventionaldose chemotherapy . Unfavorable prognostic feature include : 2. extragonadal primary site 3 . PD follow incomplete response ( IR ) firstline therapy , 4 . PD conventionaldose salvage ( cisplatin + ifosfamide base ) regimen Disease Status Enrollment : Arms A &amp; B , must fit one following : evidence disease stable , nonprogressive disease ( defined nonprogressive abnormality physical exam CT and/or MRI ) within 4 week study entry Arm C Evidence progressive recurrent GCT ( measurable nonmeasurable ) follow one cisplatinbased chemotherapy , define meeting least one follow criterion : 1 . Tumor biopsy new grow unresectable lesion demonstrate viable nonteratomatous GCT . Patients incomplete gross resection viable GCT find consider eligible . 2 . Consecutive elevated serum tumor marker ( HCG AFP ) increase . Increase elevate LDH alone constitute progressive disease . 3 . Development new enlarge lesion set persistently elevate HCG AFP , even HCG AFP continue increase . Age Performance Status Arms A &amp; B Age : 070 year Performance status : Karnofsky Performance Status least 50 % patient &gt; 16 year age Lansky Play Score least 50 patient less equal 16 year age . ( Note : Neurologic deficit patient central nervous system ( CNS ) tumor must stable minimum 1 week prior study entry Arm C Age : 070 year age Performance status : Karnofsky Performance Status ≥ 70 % patient &gt; 16 year age Lansky Play Score ≥ 70 patient ≤ 16 year age Organ Function Arm A Hematologic : hemoglobin &gt; 9 gm/dl platelet count &gt; 20,000/μl . Patients may receive transfusion necessary . Renal : Glomerular Filtration Rate ( GFR ) ≥ 50 ml/min/1.73m^2 serum creatinine ≤ 2.5 x upper limit normal ( ULN ) age Hepatic : aspartate aminotransferase alanine aminotransferase ( AST ALT ) ≤ 5 x ULN bilirubin ≤ 5 x ULN Cardiac : ejection fraction ≥ 45 % clinical evidence heart failure Pulmonary : oxygen saturation &gt; 92 % rest ( room air ) Arm B Timing : patient must fully recover radiation , induction chemotherapy surgery prior receive consolidation , minimum elapse time 2 week . Hematologic : ANC &gt; 750/µl , hemoglobin &gt; 8 gm/dl ( may receive PRBC transfusion ) platelet count &gt; 75,000/µl ( transfusion independent ) . Renal : GFR ≥ 50 ml/min/1.73m^2 Hepatic : AST ALT ≤ 2.5 x ULN bilirubin ≤ 1.5 x ULN Cardiac : ejection fraction ≥ 45 % clinical evidence heart failure Pulmonary : oxygen saturation &gt; 94 % rest ( room air ) Central Nervous System : patient seizure history allow anticonvulsant well control ; patient must status epilepticus , coma require assist ventilation Arm C Hematologic : ANC ≥ 750/mm^3 , platelet ≥ 75,000/mm^3 Renal : GFR ≥ 50 ml/min/1.73m2 serum creatinine ≤ 2.5 x ULN age Hepatic : AST ALT ≤ 2.5 x upper limit normal ( ULN ) , hepatic involvement &lt; 5 x ULN ; bilirubin ≤ 2.0 x upper limit normal ( ULN ) Arms A C : Patients history CNS tumor involvement eligible complete treatment CNS disease ( radiotherapy surgery chemotherapy ) , recovered stabilization side effect associate therapy evidence progressive CNS disease time enrollment Pregnant breastfeeding Active , uncontrolled infection and/or human immunodeficiency virus ( HIV ) positive constitute progressive disease . Concomitant enrollment clinical study ( COG study ) allow coenrollment standard care protocol ( Arm B )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>autologous transplantation</keyword>
	<keyword>high risk solid tumor</keyword>
	<keyword>relapse solid tumor</keyword>
</DOC>